• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

服用口服抗凝剂患者的临床病史和胃肠道出血。

Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants.

机构信息

Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.

Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.

出版信息

Int J Cardiol. 2021 Sep 15;339:134-137. doi: 10.1016/j.ijcard.2021.07.029. Epub 2021 Jul 17.

DOI:10.1016/j.ijcard.2021.07.029
PMID:34280423
Abstract

BACKGROUND

Common risk factors for gastrointestinal bleeding (GIB) are advanced age and the use of antiplatelet or anticoagulants drugs for the prevention of cardiovascular diseases.

METHODS

In this prospective real-world observational study, oral anticoagulated patients were recruited and followed between June 2013 and December 2019. The primary end-point was to evaluate a possible relationship between bleeding events and patients' clinical history of gastrointestinal disease prior to the start of the therapy. The secondary end-points were time of GIB appearance and the percentage of idiopathic or provoked events, i.e., bleeding due to a gastrointestinal disease. In case of GIB event all the patients were studied by means of endoscopic procedures. Cox regression was used to calculate the relative hazard ratios (HRs) of GIB for each considered clinical variable.

RESULTS

734 patients on both VKAs or DOACs were studied. Overall, 46 hemorrhagic events were recorded: 6 were major bleeding (0.42/100 patient-years) while 43 were clinically relevant non major bleeding (2.8/100 patient-years). The Cox regression analysis did not show any relationships among GIB and the variables considered.

CONCLUSION

The patients' clinical history is neither a predictor for GIB bleeding nor a guide to the choice of the oral anticoagulant to be administered. Routinely applying bleeding risk screening, such as occult blood in the stool, should be added to the periodic laboratory checks for early recognition of patients at higher risk of GIB.

摘要

背景

胃肠道出血(GIB)的常见危险因素是年龄较大和使用抗血小板或抗凝药物预防心血管疾病。

方法

在这项前瞻性真实世界观察研究中,招募了口服抗凝治疗的患者,并在 2013 年 6 月至 2019 年 12 月期间进行随访。主要终点是评估出血事件与治疗开始前患者胃肠道疾病临床史之间可能存在的关系。次要终点是 GIB 出现时间和特发性或诱发性出血(即因胃肠道疾病引起的出血)的百分比。在发生 GIB 事件的情况下,所有患者均通过内镜检查进行研究。Cox 回归用于计算 GIB 与每个考虑的临床变量相关的相对危险比(HR)。

结果

研究了 734 名同时接受 VKA 或 DOAC 治疗的患者。总体而言,记录了 46 例出血事件:6 例为大出血(0.42/100 患者年),43 例为临床相关非大出血(2.8/100 患者年)。Cox 回归分析未显示 GIB 与所考虑的变量之间存在任何关系。

结论

患者的临床病史既不能预测 GIB 出血,也不能指导选择要使用的口服抗凝剂。应常规进行出血风险筛查,例如粪便潜血,以在定期实验室检查中早期识别出血风险较高的患者。

相似文献

1
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants.服用口服抗凝剂患者的临床病史和胃肠道出血。
Int J Cardiol. 2021 Sep 15;339:134-137. doi: 10.1016/j.ijcard.2021.07.029. Epub 2021 Jul 17.
2
Risk of gastrointestinal bleeding during anticoagulant treatment.抗凝治疗期间胃肠道出血的风险。
Expert Opin Drug Saf. 2017 Jun;16(6):673-685. doi: 10.1080/14740338.2017.1325870. Epub 2017 May 17.
3
Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.口服抗凝药和非甾体抗炎药与房颤患者胃肠道出血风险的关系:一项全国性研究。
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):292-300. doi: 10.1093/ehjcvp/pvz069.
4
The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.亚洲心房颤动患者中新型口服抗凝药与维生素 K 拮抗剂之间胃肠道出血风险的荟萃分析。
Int J Environ Res Public Health. 2020 Dec 27;18(1):137. doi: 10.3390/ijerph18010137.
5
Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants.直接口服抗凝剂治疗胃肠道出血住院患者的再出血与血栓栓塞。
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1893-1900.e2. doi: 10.1016/j.cgh.2018.05.005. Epub 2018 Jun 30.
6
Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding.直接口服抗凝剂相关胃肠道出血患者的风险因素和一年死亡率。
Thromb Res. 2021 Dec;208:138-144. doi: 10.1016/j.thromres.2021.10.022. Epub 2021 Oct 28.
7
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.服用阿哌沙班或华法林的房颤患者的胃肠道出血:来自阿哌沙班减少房颤血栓栓塞事件(ARISTOTLE)试验的见解。
Am Heart J. 2020 Mar;221:1-8. doi: 10.1016/j.ahj.2019.10.013. Epub 2019 Oct 31.
8
Anticoagulant-related gastrointestinal bleeding: a real-life data analysis on bleeding profiles, frequency and etiology of patients receiving direct oral anticoagulants versus vitamin K antagonists.抗凝相关胃肠道出血:直接口服抗凝剂与维生素 K 拮抗剂患者出血情况、出血频率及病因的真实世界数据分析。
J Physiol Pharmacol. 2019 Dec;70(6). doi: 10.26402/jpp.2019.6.11. Epub 2020 Mar 20.
9
Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed.胃肠道出血住院后恢复直接口服抗凝治疗的结果。
Ann Pharmacother. 2020 Oct;54(10):975-980. doi: 10.1177/1060028020912429. Epub 2020 Mar 6.
10
Endoscopy-Related Bleeding and Thromboembolic Events in Patients on Direct Oral Anticoagulants or Vitamin K Antagonists.接受直接口服抗凝剂或维生素K拮抗剂治疗的患者的内镜相关出血和血栓栓塞事件
Clin Gastroenterol Hepatol. 2022 Mar;20(3):e380-e397. doi: 10.1016/j.cgh.2020.11.037. Epub 2020 Dec 4.

引用本文的文献

1
Oral anticoagulants-related bleeding: what happens in the emergency room? The Galeno study.口服抗凝剂相关出血:急诊室里发生了什么?加莱诺研究。
Intern Emerg Med. 2025 Aug 19. doi: 10.1007/s11739-025-04078-z.